OTLK Stock Analysis: Buy, Sell, or Hold?
OTLK - Outlook Therapeutics, Inc. Common Stock
$1.16
-0.06 (-4.92%)
▼
5d:
+60.66%
30d:
+397.43%
90d:
+229.64%
WAIT
LOW Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When OTLK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: OTLK is 30.3% above its trading range ($0.89). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: OTLK is 30.3% above its trading range ($0.89). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: OTLK is currently trading at $1.16, which is considered extended relative to its 30-day fair value range of $0.24 to $0.89.
Technical Outlook: Technically, OTLK is in a uptrend. The price is approaching resistance at $0.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: OTLK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.17 (+241.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OTLK is in a uptrend. The price is approaching resistance at $0.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: OTLK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.17 (+241.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.24 -
$0.89
Company Quality Score
55/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
42.1%
All Signals
- BEARISH: Price significantly overextended (+30.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 241.5% below Wall St target ($4.17)
Trading Range Analysis
30-Day Trading Range
$0.24 -
$0.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.40
Resistance Level
$0.94
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.57
Wall Street Target
$4.17
(+241.5%)
Revenue Growth (YoY)
658.3%
Share & Embed Analysis
Last updated: June 15, 2026 4:13 PM ET
Data refreshes hourly during market hours. Next update: 5:13 PM
Data refreshes hourly during market hours. Next update: 5:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OTLK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1029 | 64 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 51 HOLD |
